Compare Diageo plc (DEO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Zimmer Biomet Holdings Inc — how do they compare? Diageo plc trades at $87.58 (market cap $47.67B), while Zimmer Biomet Holdings Inc trades at $89.8 (market cap $16.95B). The key difference: Diageo plc is far larger — about 2.8× Zimmer Biomet Holdings Inc's market cap, and Diageo plc pays the higher dividend (2.3%). Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| DEO | ZBH | |
|---|---|---|
Market Cap | $47.67B | $16.95B |
Volume | 893,372 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $103.98 |
52-Week Low | $72.47 | $79.58 |
Typical Hold Time | 66 Days | 89 Days |
Enterprise Value | $68.09B | $24.02B |
Dividend Yield | 2.3% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $84.73, down 0.06% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 59.47% gross margin and has beaten EPS estimates in the last three quarters. Recent news highlights marketing initiatives and a CFO transition planned for 2027. The balance sheet shows $2.65B in cash against $23.75B in total debt, with a debt-to-asset ratio improving to 48.05% in 2026.
The outlook is mixed: analyst consensus leans bullish (49% buy ratings) with a focus on the US turnaround plan, but 2026 projections show declining revenue and net income. Key risks include execution of the restructuring, competitive pressures, and regulatory challenges in markets like India. The stock offers income via dividends but faces near-term fundamental headwinds.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
